Resumen de: CN118750479A
本发明公开了甜菊醇衍生物、纳米制剂及其制备方法。本发明发现了甜菊醇衍生物9#的广谱抗癌功效,不仅抑制多种癌细胞增殖,诱导癌细胞凋亡,并且在体内发挥切实有效的抗癌作用,明显抑制皮下瘤的生长。此外,通过本发明提供的包封方法将甜菊醇衍生物9#载入囊泡后,进一步提升甜菊醇衍生物9#的抗癌活性和选择性以及生物安全性,显著增强治疗效果,为临床的抗癌治疗提供了新的技术选择。
Resumen de: AU2023225913A1
The present disclosure relates to an amino lipid compound, a preparation method therefor, a composition thereof and the use thereof. Specifically, the present disclosure relates to an amino lipid compound represented by formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, and the use thereof in the preparation of a lipid nanoparticle for delivering an active ingredient. The present disclosure also relates to a composition containing the amino lipid compound, and in particular relates to a lipid nanoparticle and the use thereof.
Resumen de: CN118755084A
本发明公开了用于mRNA递送的聚合物、利用该聚合物的脂质/聚合物杂化纳米粒及其制备方法和应用,本发明阳离子聚合物的制备方法是以1,6‑己二醇二丙烯酸酯(DAHE)和亲水胺为原料通过Michael加成反应合成末端带双键前体聚合物,再以疏水胺进行封端反应而成。本发明制备含亲水主链和输水末端的聚胺基酯(poly‑β‑amino ester,PBAE),并通过在PBAE聚合物中添加(2,3‑二油酰基‑丙基)‑三甲基氯化铵(DOTAP)等辅助脂质在适当范围内提高纳米粒表面电荷,促进细胞对纳米粒的摄取,提高mRNA的递送效率。采用本发明提供的阳离子聚合物及其配方所制得的mRNA纳米制剂能够有效提高mRNA在细胞及小鼠体内的递送效率。
Resumen de: CN118750594A
本申请公开了一种二价猪口蹄疫mRNA疫苗及其制备方法和应用,属于生物技术领域中的疫苗生产技术领域。本申请要解决的技术问题是:如何有效预防猪口蹄疫病毒。为此本申请提供一种二价猪口蹄疫mRNA疫苗,所述二价猪口蹄疫mRNA疫苗含有mRNA分子1和mRNA分子2,所述mRNA分子1的核苷酸序列是SEQ ID No.5;所述mRNA分子2的核苷酸序列是SEQ ID No.6。本申请选择口蹄疫关键VP1蛋白作为mRNA抗原,利用到GAG蛋白与GP41蛋白CTD相互作用组装成VLPS原理,设计GAG融合O型VP1与A型VP1融合GP41相互作用形成二价VLPS mRNA疫苗。
Resumen de: CN118750465A
本发明涉及纳米药剂技术领域,具体涉及一种含氟脂质纳米颗粒的制备方法及应用。所述含氟脂质纳米颗粒的制备方法包括:将含氟脂质与四种商用脂质分子溶于无水乙醇,得到乙醇相脂质溶液;将核酸溶解于柠檬酸缓冲液,得到水相核酸溶液;随后将乙醇相脂质溶液与水相核酸溶液以1:3的比例匀速混合,混合物经脱盐层析柱纯化后得到本发明的含氟脂质纳米颗粒。该纳米颗粒相较于商用转染试剂和常规脂质纳米颗粒可以显著提高其核酸递送性能和转染效率。
Resumen de: CN114213508A
The invention provides a polypeptide, a polypeptide compound nanoparticle thereof, a nucleic acid vaccine and application, and belongs to the field of drug delivery. The polypeptide has the functions of compressing and protecting nucleic acid from being degraded, promoting the nucleic acid to penetrate through cell membranes and the like, and has a higher antibody effect, and the polypeptide and the polypeptide compound nanoparticles containing the polypeptide can be used for in-vivo and in-vitro cell gene transfection and can be applied to preparation of vaccine preparations.
Resumen de: CN118750453A
本发明提供了一种微环境适应性活性氧炸弹水凝胶微球及其制备与应用,属于生物材料技术领域。本发明的制备方法包括:(1)制备介孔聚多巴胺与羟基氧化铁复合纳米颗粒;(2)将葡萄糖氧化酶溶液与复合纳米颗粒混合,得到负载葡萄糖氧化酶的复合纳米颗粒;(3)将负载葡萄糖氧化酶的复合纳米颗粒进行生物矿化,得到磷酸钙包覆的葡萄糖氧化酶复合纳米颗粒;(4)制备含葡萄糖的HAMA微球,然后与复合纳米颗粒混合,即得微环境适应性活性氧炸弹水凝胶微球。本发明的微环境适应性活性氧炸弹水凝胶微球能够持续稳定高效产生·OH,具有病灶低pH响应性,定向对细菌细胞膜进行ROS攻击,使持留菌的细菌细胞膜破裂并高效诱导细菌死亡。
Resumen de: JP2024144298A
【課題】 胃酸等で分解されやすい薬剤や、単独では消化管壁透過や細胞内導入が困難な薬剤を、リポソーム、脂質ナノ粒子の状態で、ナノファイバー化した製剤、これを用いた不織布、粘膜付着製剤、脂質ナノ粒子含有ナノファイバーの製造方法を提供する。【解決手段】 ポリビニルアルコール系樹脂を含む水溶性樹脂及び脂質ナノ粒子を含有する脂質ナノ粒子含有ナノファイバー。前記水溶性樹脂中のポリビニルアルコール系樹脂の含有率が50重量%以上であることが好ましく、前記脂質ナノ粒子は代表的にはリポソームである。【選択図】 図2
Resumen de: CN114213508A
The invention provides a polypeptide, a polypeptide compound nanoparticle thereof, a nucleic acid vaccine and application, and belongs to the field of drug delivery. The polypeptide has the functions of compressing and protecting nucleic acid from being degraded, promoting the nucleic acid to penetrate through cell membranes and the like, and has a higher antibody effect, and the polypeptide and the polypeptide compound nanoparticles containing the polypeptide can be used for in-vivo and in-vitro cell gene transfection and can be applied to preparation of vaccine preparations.
Resumen de: CN118750467A
本发明公开了一种负载岩藻黄素的纳米纤维素‑玉米醇溶蛋白的核壳结构纳米颗粒的制备方法,通过将岩藻黄素负载于玉米醇溶蛋白内,并用纳米纤维素对负载岩藻黄素的玉米醇溶蛋白颗粒的表面进行修饰,进而制得具有核‑壳结构的复合纳米颗粒。本发明所得负载岩藻黄素的纳米纤维素‑玉米醇溶蛋白的核‑壳结构纳米颗粒为较透明的橘黄色,且在强酸、强碱、强紫外线及高热等极端条件下表现出优异的环境稳定性,并能大幅提升岩藻黄素的生物可及性与生物利用度。
Resumen de: CN118750468A
本发明提供一种核酸‑脂质纳米颗粒冻干组合物及其制备方法和应用,本发明属于药物制剂技术领域,所述核酸‑脂质纳米颗粒冻干组合物包括核酸‑脂质纳米颗粒和冻干保护剂,所述核酸‑脂质纳米颗粒包括核酸和脂质纳米颗粒,所述脂质纳米颗粒包括阳离子脂质、中性脂质、辅助脂质和聚合物共轭脂质,所述阳离子脂质包括可电离阳离子脂质和永久带电的阳离子脂质的组合。本发明的核酸‑脂质纳米颗粒冻干组合物产品稳定性高,在4℃条件稳定存放3个月以上。并且其冻干前后的颗粒均一性良好、包封率和mRNA完整性优异、能充分保证冻干前后的核酸不被降解;水分低、复溶时间短,理化性能优异。
Resumen de: CN114213508A
The invention provides a polypeptide, a polypeptide compound nanoparticle thereof, a nucleic acid vaccine and application, and belongs to the field of drug delivery. The polypeptide has the functions of compressing and protecting nucleic acid from being degraded, promoting the nucleic acid to penetrate through cell membranes and the like, and has a higher antibody effect, and the polypeptide and the polypeptide compound nanoparticles containing the polypeptide can be used for in-vivo and in-vitro cell gene transfection and can be applied to preparation of vaccine preparations.
Resumen de: CN118750464A
本发明涉及基因药物递送领域,具体涉及一种脂质载体、核酸脂质纳米颗粒组合物和药物制剂。本发明的脂质载体包含式I化合物、结构脂质、甾醇和PEG脂质,该脂质载体对核酸药物具有较高的包封效率,具有高效的递送效率、靶向性和安全性,具有良好的应用前景。#imgabs0#
Resumen de: US2024335571A1
The present invention provides a method of targeted molecular imaging and/or targeted drug delivery, wherein two components or probes each interacts with one or more biomarkers on a cell and separately interact with each other to form a stable bond, such as a stable covalent bond. In certain non-limiting embodiments, at least one of the probes is photo-triggered to allow for bonding with at least one second probe. In certain non-limiting embodiments, the cell is a tumor or cancer cell. The present invention also relates to compounds, probes, and kits for use in targeted molecular imaging and/or targeted drug delivery.
Resumen de: US2024335382A1
The present disclosure provides all-natural nano- or micro-emulsions for the treatment of the skin, hair follicles, and related conditions, methods of using such nano- or micro-emulsions, and methods for preparing such nano- or micro-emulsions. The present disclosure relates to nano- or micro-emulsion formulations with improved bioavailability, time of onset, cellular permeability, and viscosity that can be suitable for topical, sublingual, oral, and/or nasal administrations. The current disclosure also includes compositions and methods for improving the bioavailability and the onset of actions arising from the particular components within the nano- or micro-emulsion formulations of the present disclosure.
Resumen de: US2024335511A1
This disclosure relates to the field of therapeutic RNA to treat cancer, in particular advanced solid tumors such as metastatic (Stage IV) or unresectable localized cancer. Disclosed herein are compositions, uses, and methods for treatment of cancers. Administration of therapeutic RNAs to a patient having cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.
Resumen de: US2024335515A1
Enzyme-loaded polymeric nanoparticles for the treatment of disorders such as neurological or non-neurological conditions are described. Using hydrophobic ion pairing, enzymes are loaded into polymeric nanoparticles while retaining enzymatic activity. Surfactants coating the nanoparticle can direct nanoparticles for cellular uptake or for aggregation in the extracellular matrix. Preparing a hydrophobic ion pairing complex for nanoparticle formation.
Resumen de: US2024335527A1
Disclosed herein are compositions of disaggregated spherical nanostructures comprising Quil-A and dioleoyl 3 trimethylammonium propane (DOTAP) wherein the Quil-A and DOTAP are present at ratios between 2:1 Quil-A: DOTAP to about 1:2 Quil-A: DOTAP. Also provided are methods of making and using the same.
Resumen de: US2024335508A1
Provided herein are gold nanoparticles (AuNPs) and therapeutics agents co-encapsulated within non-ionic surfactant vehicles (AuNSVs) as well as therapeutic methods of using AuNSVs. Also provided herein are a millifluidic synthesis apparatus and process using ultrasonic mixing for producing AuNSVs encapsulating therapeutic or diagnostic agents, such as chemotherapeutics and/or mRNA.
Resumen de: US2024335393A1
Provided are empty lipid nanoparticle compositions, and processes for their preparation, which are useful in the preparation of therapeutic or prophylactic lipid nanoparticle compositions comprising a therapeutic or prophylactic agent including, for example, nucleic acids such as mRNA.
Resumen de: US2024335391A1
The application discloses a formulation and method for increasing bioavailability of an orally administered drug.
Resumen de: US2024335385A1
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
Resumen de: US2024335392A1
In one aspect, the disclosure relates to nanoclusters comprising cores comprising self-assembled unimolecular nanoparticles and biomimetic membrane coatings surrounding the cores, methods of making the same, and methods of treating and preventing restenosis using same. In some embodiments, the nanoclusters can contain an anti-restenotic drug. In one embodiment, the polymers and/or copolymers of the unimolecular nanoparticles can contain a hydrophobic group such as, for example, a phenylboronic ester. In a further embodiment, the biomimetic membrane can localize the nanoclusters at sites of vascular damage, at which time reactive oxygen species (ROS) at the sites of vascular damage cleave the hydrophobic groups from the polymers and/or copolymers, increasing hydrophilicity of the polymers and/or copolymers and allowing for greater tissue penetration of the de-clustered nanoclusters and nanoparticles.
Resumen de: US2024335396A1
The nano liquid composition containing curcumin have the ability to treating burns and increasing the effect of scar healing obtained by homogenously mixing a curcumin nano ingredient with a foundation mixture in a ratio of 1:1 by emulsifying equipment. The composition overcomes the disadvantages of curcumin, an organic compound with a broad spectrum of activities, including hard to dissolve in water, poor stability, and rapidly transformed. In addition, the composition of the present invention is used at a dose of 0.05-0.1 mL/cm 2 of skin, with a frequency of twice daily, had increased effect of scar healing in experimental doxorubicin-induced mouse models of skin ulceration, increased concentration of hydroxyprolin in skin, improved skin microstructure compared to control models after 21 days of application; and had no systemic toxicity after 21 days of application in the doxorubicin-induced skin ulcered mouse.
Nº publicación: US2024335383A1 10/10/2024
Solicitante:
NEWIMMUNE II LLC [US]
NewImmune II, LLC
Resumen de: US2024335383A1
The present disclosure relates to nanoparticles and nanoparticulate compositions; methods of preparing such nanoparticles and nanoparticulate compositions; and associated methods of medical treatment and uses of such nanoparticles and nanoparticulate compositions for medical treatment, including the use of such nanoparticles for the manufacture of medicaments for medical treatment.